Evidence map›Paper›PMID 26322014›Full record

ReviewFrontiers in neurology2015

Current Understanding of Circulating Tumor Cells - Potential Value in Malignancies of the Central Nervous System.

Lukasz A Adamczyk, Hannah Williams, Aleksandra Frankow, Hayley Patricia Ellis, Harry R Haynes, Claire Perks, Jeff M P Holly, Kathreena M Kurian

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in neurology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Review
  3. Liquid biopsy techniques and lung cancer: diagnosis, monitoring and evaluation.Journal of experimental & clinical cancer research : CR · 2024
    Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Liquid Biomarkers for Improved Diagnosis and Classification of CNS Tumors.International journal of molecular sciences · 2021
    Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Biomarkers for glioblastoma multiforme: status quo.Journal of clinical and translational research · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Lukasz A AdamczykDepartment of Cellular Pathology, North Bristol NHS Trust , Bristol , UK.
Hannah WilliamsBrain Tumor Research Group, Institute of Clinical Neuroscience, North Bristol NHS Trust , Bristol , UK.
Aleksandra FrankowIGF and Metabolic Endocrinology Group, School of Clinical Sciences, North Bristol NHS Trust, University of Bristol , Bristol , UK.
Hayley Patricia EllisBrain Tumor Research Group, Institute of Clinical Neuroscience, North Bristol NHS Trust , Bristol , UK.
Harry R HaynesBrain Tumor Research Group, Institute of Clinical Neuroscience, North Bristol NHS Trust , Bristol , UK.
Claire PerksIGF and Metabolic Endocrinology Group, School of Clinical Sciences, North Bristol NHS Trust, University of Bristol , Bristol , UK.
Jeff M P HollyIGF and Metabolic Endocrinology Group, School of Clinical Sciences, North Bristol NHS Trust, University of Bristol , Bristol , UK.
Kathreena M KurianBrain Tumor Research Group, Institute of Clinical Neuroscience, North Bristol NHS Trust , Bristol , UK.
North Bristol NHS Trust · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Detection of circulating tumor cells (CTCs) in the blood via so-called "liquid biopsies" carries enormous clinical potential in malignancies of the central nervous system (CNS) because of the potential to follow disease evolution with a blood test, without the need for repeat neurosurgical procedures with their inherent risk of patient morbidity. To date, studies in non-CNS malignancies, particularly in breast cancer, show increasing reproducibility of detection methods for these rare tumor cells in the circulation. However, no method has yet received full recommendation to use in clinical practice, in part because of lack of a sufficient evidence base regarding clinical utility. In CNS malignancies, one of the main challenges is finding a suitable biomarker for identification of these cells, because automated systems, such as the widely used Cell Search system, are reliant on markers, such as the epithelial cell adhesion molecule, which are not present in CNS tumors. This review examines methods for CTC enrichment and detection, and reviews the progress in non-CNS tumors and the potential for using this technique in human brain tumors.

Indexed as

circulating tumor cellsepithelial–mesenchymal transitionglioblastoma multiformegliomaliquid biopsy

Identifiers

PMID26322014
PMCPMC4530310
OpenAlexW1910266551

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.